The purpose of this study is to look at the safety and effectiveness of dextrin sulfate in
AIDS patients who have failed conventional anti-HIV treatment.
Patients have intraperitoneal (IP) catheter placement done at study entry. Infusion with the
carrier vehicle (icodextrin 4%) begins 2 weeks later, and 2 days after that, treatment with
dextrin sulphate (DS) commences. DS is given three times per week. A nurse delivers initial
treatments and the patient and caregiver will be trained to give subsequent treatments until
DS has been given a total of 8 weeks. Patient evaluations are done regularly during
treatment and observation continues for 24 weeks.
Patients may be eligible for this trial if they:
- Are HIV-positive.
- Have been diagnosed with AIDS and are under treatment to prevent opportunistic
- Have had a CD4 cell count greater than 50 microL for at least the past 3 months.
- Have had a viral load of at least 50,000 copies/ml for at least the past 3 months.
- Have used up all other treatment options.
- Are able to understand and give written consent.
Patients may not be eligible for this trial if they:
- Have been in any other study in the 6 weeks before beginning this study.
- Have an active, opportunistic infection or other infection.
- Have any other long-term medical condition or nervous disorder that might make it
difficult for them to finish the study.